Vaxxinity (Vaxxinity) Net Change in Cash : $-29.53 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Vaxxinity's Net Change in Cash for the three months ended in Dec. 2023 was $-12.57 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-29.53 Mil.

Vaxxinity Net Change in Cash Historical Data

The historical data trend for Vaxxinity's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity Net Change in Cash Chart

Vaxxinity Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

-1.13

30.72

113.86

-110.49

-29.53

Vaxxinity Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial											12.62	-11.89	14.58	-19.66	-12.57

Vaxxinity Net Change in Cash Calculation

Vaxxinity's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-57.238	+	28.844	+	-1.14	+	0
	=	-29.53

Vaxxinity's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -11.845 + -0.407 + -0.313 + 0

= -12.57

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxxinity Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Vaxxinity's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxxinity (Vaxxinity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » Net Change in Cash

Comparable Companies

CYDY ALDX RPTX APLT ATNM LYRA MRSN VRCA GRPH FHTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

N/A

Address

505 Odyssey Way, Merritt Island, FL, USA, 32953

Website

https://www.vaxxinity.com

Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.

Executives

Sumita Ray officer: Chief Legal Officer, Secretary C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085

Prime Movers Lab Fund I Lp 10 percent owner P.O. BOX 12829, JACKSON WY 83002

Landon E Ogilvie director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953

Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746

James Alan Smith director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953

Gabrielle B Toledano director 209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065

Lou Reese director, officer: Executive Chairman C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201

Mei Mei Hu director, 10 percent owner, officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201

United Biomedical Inc 10 percent owner 25 DAVIDS DR, HAUPPAUGE NY 11788

Dakin Sloss 10 percent owner 126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022

Peter Powchik director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591

Jason Pesile officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201

George R Hornig director 625 MADISON AVE SUITE 10-B, NEW YORK NY 10017

James Chui director C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201

Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292

Vaxxinity (Vaxxinity) Headlines

From GuruFocus

Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines
By GlobeNewswire GlobeNewswire • 07-25-2022

Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines
By PurpleRose PurpleRose • 07-25-2022

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates
By GuruFocusNews GuruFocusNews • 07-08-2022

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease
By Marketwired • 06-22-2023

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia
By Value_Insider Value_Insider • 10-24-2022

Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients
By Marketwired • 07-17-2023

Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida
By Stock market mentor Stock market mentor • 02-02-2023

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
By sperokesalga sperokesalga • 05-09-2023

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
By sperokesalga sperokesalga • 03-20-2023

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates
By GuruFocusNews GuruFocusNews • 06-28-2022

Sumita Ray	officer: Chief Legal Officer, Secretary	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp	10 percent owner	P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade	director	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano	director	209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese	director, officer: Executive Chairman	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu	director, 10 percent owner, officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc	10 percent owner	25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss	10 percent owner	126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile	officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig	director	625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui	director	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292